Billiontoone (BLLN) Stock Price, News & Analysis

Company Overview

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics. Its technology aims to improve accuracy in detecting fetal aneuploidies, microdeletions, and single-gene disorders from maternal blood samples by reducing measurement noise and enabling precise digital quantification. The company provides testing services and partners with clinical laboratories, healthcare providers, and research organizations to implement its assays in clinical and research settings.

In support of clinical adoption, BillionToOne focuses on analytical validation, clinical studies, and building laboratory processes that integrate its single-molecule counting approach into standard diagnostic pipelines. The company positions its platform as complementary to existing sequencing and molecular methods, emphasizing improved detection of low-frequency variants and potential reductions in false positives that can drive follow-up invasive procedures.

BillionToOne serves the healthcare and clinical diagnostics market, primarily through collaborations and laboratory channels. Its management and scientific teams are oriented toward translating advanced genomic measurement techniques into deployable clinical tests, with ongoing efforts to expand the clinical utility and accessibility of its assays through partnerships and regulatory and clinical validation activities.

Key Stats

• Today's Range: $85.10 to $93.99
• 50-Day Range: $64.03 to $92.90
• 52-Week Range: $61.96 to $138.70
• Volume: 677,929 shs
• Average Volume: 346,725 shs
• Market Capitalization: $4.10 billion
• P/E Ratio: 424.38
• Dividend Yield: N/A
• Price Target: $122.43
• Consensus Rating: Moderate Buy

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Services
• Industry: Services – Health
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BLLN
• CIK: 2070849
• Web: N/A
• Phone: (650) 460-2551
• Fax: N/A
• Employees: 620
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Billiontoone: $122.43
• High Price Target: $150.00
• Low Price Target: $90.00
• Potential Upside/Downside: +38.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 423.36
• Forward P/E Ratio: 210.96
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 11.69
• Quick Ratio: 11.32

Sales & Book Value

• Annual Sales: $354.54 million
• Price / Sales: 11.49
• Cash Flow: $0.35 per share
• Price / Cash Flow: 251.48
• Book Value: $10.48 per share
• Price / Book: 8.45

Miscellaneous

• Outstanding Shares: 45,966,000
• Free Float: N/A
• Market Cap: $4.07 billion
• Optionable: N/A
• Beta: N/A